Azurrx Biopharm (AZRX) Shares Bought by Parsons Capital Management Inc. RI

Parsons Capital Management Inc. RI boosted its stake in Azurrx Biopharm (NASDAQ:AZRX) by 37.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 254,263 shares of the company’s stock after buying an additional 68,920 shares during the period. Parsons Capital Management Inc. RI owned 2.26% of Azurrx Biopharm worth $1,015,000 as of its most recent SEC filing.

Separately, Ardsley Advisory Partners acquired a new stake in Azurrx Biopharm in the second quarter worth $141,000. 5.99% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Azurrx Biopharm (AZRX) Shares Bought by Parsons Capital Management Inc. RI” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at

Separately, HC Wainwright set a $8.00 target price on Azurrx Biopharm and gave the stock a “buy” rating in a research report on Monday, October 23rd.

Azurrx Biopharm (AZRX) opened at $2.81 on Wednesday. Azurrx Biopharm has a fifty-two week low of $2.60 and a fifty-two week high of $5.25.

Azurrx Biopharm Profile

AzurRx BioPharma, Inc is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101.

Receive News & Ratings for Azurrx Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azurrx Biopharm and related companies with's FREE daily email newsletter.

Leave a Reply